secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001558370-22-017561
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hookipa Q3 net loss $18.3M; cash $100.7M; secured Roche deal for KRAS-mutated cancers
--------------------------------------------------------------------------------

- Net loss $18.3M in Q3 2022 vs $20.0M in Q3 2021; revenue $2.2M (down from $3.9M).
- Cash $100.7M as of Sep 30, 2022 (up from $66.9M Dec 2021); excludes $25M Roche upfront and up to $30M Gilead stock purchase.
- Entered Roche collaboration for HB-700 (KRAS-mutated cancers) and second candidate; $25M upfront, potential $930M milestones plus royalties.
- FDA accepted IND for HB-300 (metastatic castration-resistant prostate cancer); Phase 1 start expected Q1 2023.
- Phase 2 HB-200 + pembrolizumab data expected H1 2023; >20 patients dosed, enrollment ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000155837022017561/0001558370-22-017561-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000155837022017561/hook-20221114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-017561

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer